Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.
about
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with antiretrovirals (OPTIMA) studyPredicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Combining epidemiologic and biostatistical tools to enhance variable selection in HIV cohort analyses.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkersAn internationally generalizable risk index for mortality after one year of antiretroviral therapy.Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countriesPrognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programsCauses of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study.Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesPredictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysisImportance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.Body Composition Features Predict Overall Survival in Patients With Hepatocellular CarcinomaDeveloping a predictive risk model for first-line antiretroviral therapy failure in South AfricaCross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators.Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Identifying representative trees from ensembles.The clinical outcome after coronary bypass surgery: a 30-year follow-up study.Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services.Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy.
P2860
Q24597052-14D9A2BE-39EF-4186-96BC-CA89C6F4EDC7Q24656950-1831CD8D-ED84-40C7-B5B8-F0BE86571E36Q28541478-E0066B77-AF68-40EC-BEB7-1C2C7EEA2D7AQ30573969-BC031470-55FA-42DC-8E74-FA97F4F18980Q31149210-6A03A588-AA3B-4205-ACF3-04615805D2CDQ33602915-723D3878-2A37-4E02-ACF5-A7C4D96436B9Q33736040-81B7F600-AE58-4436-9D3D-5EACDDF459AEQ33881303-D309FD8C-0652-4CC9-8236-46650BA94C2CQ34802684-C8BB1533-ABD7-45E9-9DA2-73FE9030152DQ34813110-C9328E10-F216-4BB3-A5DD-5E4ED0B7B05CQ34851822-58CA7447-D391-446B-9FDB-A3C43F42CCFCQ35057962-4FCB95BB-ABD6-4495-A556-57EEF28EC9BBQ35111146-5AED2FB8-039C-42B2-A8D5-00084521E64AQ35148237-10A07108-1CBE-4432-AC7F-C2F6F62118DEQ35169664-655A5032-AD61-4779-8D18-7BD916A6A4F5Q35772030-C57465AF-0681-4BE4-A418-184BF78332CBQ35867142-8EDB35C6-0150-4EF0-9679-7AA2D540B96BQ35962516-F0860A3D-3C48-4029-B2E2-F7F8A7F01C35Q36285986-923AE53B-D0C9-492C-B318-C9BC7D8A4B30Q36747893-A057495C-FF5E-4991-95A7-0E6590F3D09BQ36943004-8A0D3F91-3AF9-4B11-A03F-FD96EAC91535Q36970515-31C7E230-F8BC-4020-8F0A-F1DD44969DEEQ37290134-A694E5A8-6453-4E53-8A5B-12BF8ED6A157Q37354933-007B3B2C-B415-4BDE-899D-01734861181CQ37378521-5EA6D209-C999-4E4E-B7E6-BA98F03A3DFAQ37475726-87975F73-FE01-4CE6-8F93-0D5A23B5CA4BQ39657014-06D31A00-F035-42A2-9F25-88E6A40614DEQ43637499-D506B49F-C118-4F31-A74B-FD1A9A3DA548Q44001612-BD8C514F-725B-4136-9652-C6311E5D3DCFQ47241444-1C1C983B-35A4-4727-8C2B-B10AFECFD7C1
P2860
Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Development and validation of ...... d with antiretroviral therapy.
@ast
Development and validation of ...... d with antiretroviral therapy.
@en
type
label
Development and validation of ...... d with antiretroviral therapy.
@ast
Development and validation of ...... d with antiretroviral therapy.
@en
prefLabel
Development and validation of ...... d with antiretroviral therapy.
@ast
Development and validation of ...... d with antiretroviral therapy.
@en
P2093
P50
P356
P1476
Development and validation of ...... d with antiretroviral therapy.
@en
P2093
ART Cohort Collaboration
Amy C Justice
Jonathan A C Sterne
P304
P356
10.1002/SIM.1825
P407
P577
2004-08-01T00:00:00Z